Omar Alhalabi
Overview
Explore the profile of Omar Alhalabi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moussa M, Kovalenko I, Crupi E, Proskuriakova E, Geng Y, Fallara G, et al.
Bladder Cancer
. 2025 Mar;
10(4):300-312.
PMID: 40035076
Background: Antiangiogenic therapy had been tested in urothelial cancer (UC) without reaching the clinic. Objective: We provide a systematic review and meta-analysis of trials to assess efficacy of immune checkpoint...
2.
Alhalabi O, Gouda M, Milton D, Momin H, Yilmaz B, Stephen B, et al.
Cancer Med
. 2025 Feb;
14(4):e70280.
PMID: 39945382
Background: Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL...
3.
Moussa M, Khandelwal J, Wilson N, Malikayil K, Surasi D, Bathala T, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39939142
Background: Nivolumab plus ipilimumab (nivo/ipi) is a standard of care first-line (1 L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC), but its role in patients with metastatic,...
4.
Moussa M, Tabet G, Siefker-Radtke A, Xiao L, Wilson N, Gao J, et al.
Cancer Med
. 2025 Jan;
14(2):e70594.
PMID: 39831734
Introduction: Small cell neuroendocrine carcinoma of the urinary tract (SCNEC-URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after...
5.
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39709257
Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in...
6.
Crupi E, de Padua T, Marandino L, Fallara G, Pederzoli F, Cimadamore A, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400470.
PMID: 39626158
Purpose: Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of the bladder (UBC). Limited data on...
7.
Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell M, Shah A, et al.
Clin Transl Radiat Oncol
. 2024 Oct;
49:100866.
PMID: 39403573
Purpose: Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We...
8.
Benkhadra R, Nayfeh T, Patibandla S, Peterson C, Prokop L, Alhalabi O, et al.
Bladder Cancer
. 2024 Jul;
8(1):5-17.
PMID: 38994516
Background: Cisplatin-based neoadjuvant chemotherapy is the standard of care for muscle invasive bladder cancer (MIBC). Objective: To compare the efficacy and safety of the two most commonly used cisplatin-based regimens;...
9.
Moussa M, Khandelwal J, Wilson N, Naik S, Subbiah V, Campbell M, et al.
Curr Oncol
. 2024 Jun;
31(6):3342-3349.
PMID: 38920737
Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes (, ) and amplifications in...
10.
Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat A, Alhalabi O, et al.
Hum Pathol
. 2024 Apr;
148():1-6.
PMID: 38679207
Plasmacytoid urothelial carcinoma (UC) is a rare histologic subtype of bladder cancer that is associated with an aggressive clinical behavior. We analyzed the clinicopathologic and molecular features of plasmacytoid UC...